Contezolid (MRX-4/MRX-1)

MicuRx Pharmaceuticals, Inc.
Contezolid, MRX-4/MRX-1
Chemical Class:
Name of Target:
Protein Synthesis. Binding to the V region of 23S rRNA

MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). Orally administered MRX-I showed the same or better efficacy than linezolid in systemic and local infection mouse models.

MRX-1 is in Phase 3 clinical trial in China.

MRX4, a prodrug of MRX-1, is in Phase 1 trial in the U.S.  MicruRX Press Release November 30,2016.


Developer Associations